We firstly report here that TMEM211 promotes cancer progression and EMT for metastasis in colon cancer through coactivating the ERK, AKT and NF-κB signaling pathways, which implies that TMEM211 might be a potential prognostic biomarker and target for the treatment of colon cancer patients in the future. Here, NFKB1 is linked to malignant colon neoplasm.